Praxis Precision Medicines, Inc. (PRAX) shareholders
Close on Nov 17, 2026Market cap $8.52BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC Joint filing with Janus Henderson Biotech Innovation Master Fund Ltd (6.20%) | 2,763,859 | 12.30% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (9.20%) | 2,565,828 | 9.20% | 13G (passive) amendment | Sep 30, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (7.20%), Joseph Edelman (7.20%) | 1,995,986 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (9.69%), Phillip Gross (9.69%) | 1,974,585 | 9.69% | 13G (passive) amendment | Jun 30, 2025 |
| Julian C. Baker Joint filing with Baker Bros. Advisors LP (6.30%), Baker Bros. Advisors (GP) LLC (6.30%) and 1 more | 1,753,198 | 6.30% | 13G (passive) | Mar 31, 2026 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (5.90%), Point72 Capital Advisors, Inc. (5.90%) | 1,569,309 | 6.10% | 13G (passive) amendment | Dec 31, 2025 |
| Orbis Investment Management Ltd | 1,526,680 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 1,419,323 | 5.09% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 1,302,435 | 7.30% | 13G (passive) | Sep 30, 2024 |
| Guy Levy Joint filing with Soleus Capital Master Fund, L.P. (5.00%), Soleus Capital, LLC (5.00%) and 3 more | 1,017,740 | 5.00% | 13G (passive) | Mar 18, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PRAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 3,421,374 | 12.25% | $1.15B | New | 0.47% |
| FMR LLC | 2,316,907 | 8.30% | $775.68M | +155,964 | 0.03% |
| BlackRock, Inc. | 2,292,585 | 8.21% | $767.53M | −32,344 | 0.01% |
| Perceptive Advisors LLC | 2,035,986 | 7.29% | $681.63M | – | 10.23% |
| Baker Bros. Advisors LP | 1,753,198 | 6.28% | $586.95M | – | 2.94% |
| Orbis Allan Gray Ltd | 1,529,788 | 5.48% | $512.16M | −942,692 | 1.76% |
| Vanguard Portfolio Management LLC | 1,335,185 | 4.78% | $447.01M | +578,437 | 0.02% |
| Vanguard Capital Management LLC | 1,235,299 | 4.42% | $413.57M | +13,355 | 0.01% |
| State Street Corp | 1,026,443 | 3.68% | $343.66M | +142,205 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,015,480 | 3.64% | $339.97M | +199,741 | 0.48% |
| Deerfield Management Company, L.P. (Series C) | 963,351 | 3.45% | $322.52M | – | 3.36% |
| Driehaus Capital Management LLC | 959,048 | 3.43% | $321.08M | +9,823 | 1.86% |
| Price T Rowe Associates Inc /Md/ | 942,999 | 3.38% | $315.71M | +312,147 | 0.03% |
| Morgan Stanley | 854,112 | 3.06% | $285.95M | +20,621 | 0.02% |
| Geode Capital Management, LLC | 748,039 | 2.68% | $250.48M | +97,135 | 0.01% |
| Cormorant Asset Management, LP | 640,000 | 2.29% | $214.27M | −245,500 | 10.98% |
| Goldman Sachs Group Inc | 548,830 | 1.97% | $183.74M | −161,904 | 0.02% |
| Bank Of America Corp /De/ | 546,930 | 1.96% | $183.11M | +12,326 | 0.01% |
| Invesco Ltd. | 537,548 | 1.93% | $179.97M | +476,151 | 0.01% |
| Hood River Capital Management LLC | 425,167 | 1.52% | $142.34M | +66,549 | 1.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 309 | 34M | 100.0% | 60 / 122 | 93 / 39 | 8M | 3M |
| Q1 2026 | 291 | 32M | 100.0% | 80 / 120 | 69 / 33 | 7M | 3M |
| Q4 2025 | 250 | 29M | 100.0% | 115 / 87 | 44 / 15 | 10M | 5M |
| Q3 2025 | 152 | 25M | 88.5% | 28 / 59 | 45 / 19 | 5M | 4M |
| Q2 2025 | 143 | 24M | 86.6% | 25 / 65 | 35 / 32 | 5M | 4M |
| Q1 2025 | 150 | 23M | 84.0% | 34 / 47 | 52 / 45 | 6M | 4M |
| Q4 2024 | 162 | 22M | 77.8% | 38 / 55 | 53 / 10 | 5M | 2M |
| Q3 2024 | 134 | 19M | 67.6% | 35 / 43 | 45 / 13 | 5M | 4M |
| Q2 2024 | 113 | 18M | 66.0% | 38 / 42 | 26 / 35 | 6M | 4M |
| Q1 2024 | 111 | 16M | 57.9% | 60 / 29 | 17 / 7 | 10M | 2M |
| Q4 2023 | 58 | 8M | 28.4% | 58 / 0 | 0 / 0 | 8M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
395 funds held PRAX in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PRAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 885,411 | 3.17% | $296.43M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 653,110 | 2.34% | $218.65M | 0.26% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 639,578 | 2.29% | $214.12M | 0.11% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 413,737 | 1.48% | $138.52M | 1.29% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 405,016 | 1.45% | $135.60M | 0.20% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 379,352 | 1.36% | $127.00M | 2.19% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 371,429 | 1.33% | $129.99M | 2.47% | May 31, 2026 |
| Janus Henderson Enterprise Fund | 358,092 | 1.28% | $119.89M | 0.54% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 300,868 | 1.08% | $100.73M | 0.10% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 274,766 | 0.98% | $84.58M | 0.25% | Jul 31, 2026 |
| Janus Henderson Triton Fund | 247,753 | 0.89% | $82.95M | 1.40% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 236,569 | 0.85% | $79.20M | 0.54% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 233,232 | 0.84% | $78.08M | 0.51% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 186,930 | 0.67% | $57.54M | 0.65% | Jul 31, 2026 |
| iShares Biotechnology ETF | 185,012 | 0.66% | $61.94M | 0.68% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marcio Souza | Chief Executive Officer, Director | 56,495 | 0.20% | Jul 8, 2026 |
| Timothy Edwin Kelly | Chief Financial Officer | 31,167 | 0.11% | May 19, 2026 |
| Megan Sniecinski | Chief Operating Officer | 28,664 | 0.10% | May 19, 2026 |
| Lauren Mastrocola | Principal Accounting Officer | 13,573 | 0.05% | May 19, 2026 |
| Alex Nemiroff | General Counsel and Secretary | 26,011 | 0.09% | May 19, 2026 |
| Jill DeSimone | Director | 13,807 | 0.05% | Jun 26, 2026 |
| Merit Ester Cudkowicz | Director | 1,371 | 0.00% | Jun 12, 2026 |
| Jeffrey B. Kindler | Director | 2,537 | 0.01% | Jun 12, 2026 |
| William D. Young | Director | 3,269 | 0.01% | Jun 12, 2026 |
| Stuart A. Arbuckle | Director | 2,537 | 0.01% | Jun 12, 2026 |
| Gregory Norden | Director | 1,559 | 0.01% | Jun 12, 2026 |
| Dean J. Mitchell | Director | 18,622 | 0.07% | Jun 12, 2026 |
| Jeffrey Chodakewitz | Director | 1,371 | 0.00% | Jun 12, 2026 |
| Robert Atchinson | 10% owner | 2,374,085 | 8.50% | Oct 17, 2025 |
| Phillip Gross | 10% owner | 2,080,168 | 7.45% | Oct 17, 2025 |
| Adage Capital Management, L.P. | 10% owner | – | – | Oct 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marcio Souza Chief Executive Officer, Director | Jul 8, 2026 | Gift | −2,600 | – | – | 0 |
| Marcio Souza Chief Executive Officer, Director | Jul 8, 2026 | Gift | −20,521 | – | – | 56,495 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −120 | $303.13 | $36.38K | 13,807 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −320 | $305.31 | $97.70K | 13,487 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −683 | $306.77 | $209.52K | 12,804 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −1,240 | $308.24 | $382.22K | 11,564 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −999 | $309.38 | $309.07K | 10,565 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −1,750 | $310.89 | $544.06K | 8,815 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −2,854 | $311.91 | $890.19K | 5,961 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −1,004 | $312.83 | $314.08K | 4,957 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −504 | $313.66 | $158.08K | 4,453 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −837 | $315.71 | $264.25K | 2,337 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −1,279 | $314.90 | $402.76K | 3,174 |
| Jill DeSimone Director | Jun 24, 2026 | Option exercise | +8,566 | $44.25 | $379.05K | 10,903 |
| Jill DeSimone Director | Jun 24, 2026 | Option exercise | +3,034 | $147.30 | $446.91K | 13,937 |
| Jill DeSimone Director | Jun 24, 2026 | Sale(10b5-1 plan) | −10 | $301.44 | $3.01K | 13,927 |
| Gregory Norden Director | Jun 10, 2026 | Award | +1,371 | – | – | 1,559 |
| Stuart A. Arbuckle Director | Jun 10, 2026 | Award | +1,371 | – | – | 2,537 |
| Jeffrey Chodakewitz Director | Jun 10, 2026 | Award | +1,371 | – | – | 1,371 |
| Jill DeSimone Director | Jun 10, 2026 | Award | +1,371 | – | – | 2,337 |
| Merit Ester Cudkowicz Director | Jun 10, 2026 | Award | +1,371 | – | – | 1,371 |
| William D. Young Director | Jun 10, 2026 | Award | +1,371 | – | – | 3,269 |
| Jeffrey B. Kindler Director | Jun 10, 2026 | Award | +1,371 | – | – | 2,537 |
| Dean J. Mitchell Director | Jun 10, 2026 | Award | +1,371 | – | – | 18,622 |
| Megan Sniecinski Chief Operating Officer | May 14, 2026 | Award | +89 | $167.94 | $14.95K | 28,664 |
| Marcio Souza Chief Executive Officer, Director | May 14, 2026 | Award | +126 | $167.94 | $21.16K | 77,016 |
| Timothy Edwin Kelly Chief Financial Officer | May 14, 2026 | Award | +121 | $167.94 | $20.32K | 31,167 |
| Alex Nemiroff General Counsel and Secretary | May 14, 2026 | Award | +78 | $167.94 | $13.10K | 26,011 |
| Lauren Mastrocola Principal Accounting Officer | May 14, 2026 | Award | +127 | $167.94 | $21.33K | 13,573 |
| Jeffrey B. Kindler Director | Feb 6, 2026 | Award | +688 | – | – | 688 |
| Jeffrey B. Kindler Director | Feb 6, 2026 | Award | +478 | – | – | 1,166 |
| Stuart A. Arbuckle Director | Feb 6, 2026 | Award | +478 | – | – | 1,166 |
| Stuart A. Arbuckle Director | Feb 6, 2026 | Award | +688 | – | – | 688 |
| Megan Sniecinski Chief Operating Officer | Jan 12, 2026 | Tax withholding | −885 | $275.74 | $244.03K | 28,530 |
| Alex Nemiroff General Counsel and Secretary | Jan 12, 2026 | Tax withholding | −768 | $275.74 | $211.77K | 25,933 |
| Lauren Mastrocola Principal Accounting Officer | Jan 12, 2026 | Tax withholding | −344 | $275.74 | $94.85K | 13,446 |
| Timothy Edwin Kelly Chief Financial Officer | Jan 12, 2026 | Tax withholding | −943 | $275.74 | $260.02K | 31,046 |
| Lauren Mastrocola Principal Accounting Officer | Jan 10, 2026 | Tax withholding | −367 | $288.45 | $105.86K | 13,790 |
| Timothy Edwin Kelly Chief Financial Officer | Jan 10, 2026 | Tax withholding | −1,335 | $288.45 | $385.08K | 31,989 |
| Megan Sniecinski Chief Operating Officer | Jan 10, 2026 | Tax withholding | −1,087 | $288.45 | $313.55K | 29,415 |
| Alex Nemiroff General Counsel and Secretary | Jan 10, 2026 | Tax withholding | −917 | $288.45 | $264.51K | 26,701 |
| Marcio Souza Chief Executive Officer, Director | Jan 10, 2026 | Tax withholding | −4,252 | $288.45 | $1.23M | 76,890 |
| Lauren Mastrocola Principal Accounting Officer | Jan 8, 2026 | Award | +3,750 | – | – | 14,157 |
| Timothy Edwin Kelly Chief Financial Officer | Jan 8, 2026 | Award | +8,800 | – | – | 33,324 |
| Megan Sniecinski Chief Operating Officer | Jan 8, 2026 | Award | +9,625 | – | – | 30,502 |
| Alex Nemiroff General Counsel and Secretary | Jan 8, 2026 | Award | +6,875 | – | – | 27,618 |
| Marcio Souza Chief Executive Officer, Director | Jan 8, 2026 | Award | +27,640 | – | – | 81,142 |
| Timothy Edwin Kelly Chief Financial Officer | Jan 7, 2026 | Tax withholding | −139 | $292.63 | $40.68K | 24,524 |
| Alex Nemiroff General Counsel and Secretary | Jan 7, 2026 | Tax withholding | −89 | $292.63 | $26.04K | 20,743 |
| Lauren Mastrocola Principal Accounting Officer | Jan 7, 2026 | Tax withholding | −35 | $292.63 | $10.24K | 10,407 |
| Marcio Souza Chief Executive Officer, Director | Jan 7, 2026 | Tax withholding | −405 | $292.63 | $118.52K | 53,502 |
| Marcio Souza Chief Executive Officer, Director | Dec 30, 2025 | Gift | −400 | – | – | 2,600 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +508 | $83.85 | $42.60K | 11,997 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +1,557 | $133.65 | $208.09K | 13,554 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +2,680 | $43.37 | $116.23K | 16,234 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +207 | $44.40 | $9.19K | 16,441 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +1,047 | $49.50 | $51.83K | 11,489 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +2,351 | $44.40 | $104.38K | 18,792 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Option exercise | +5,250 | $56.94 | $298.94K | 24,042 |
| Lauren Mastrocola Principal Accounting Officer | Nov 20, 2025 | Sale | −11,455 | $191.96 | $2.20M | 12,587 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Praxis Precision Medicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,972 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jill DeSimone Director | Jun 24, 2026 | 11,600 | $3.61M | Jun 24, 2026 | Stock Option Exercise |
| Lauren Mastrocola Officer | Nov 20, 2025 | 13,600 | $2.61M | Nov 20, 2025 | Option Granted - 09/24/2019 |
| Alex Nemiroff Officer | Nov 20, 2025 | 25,130 | $4.85M | Nov 20, 2025 | Options Granted - 07/29/2024 |
| Lauren Mastrocola Officer | Nov 14, 2024 | 5,189 | $424.32K | Nov 14, 2024 | Option Granted 07/29/2024 |
| Alex Nemiroff Officer | Nov 14, 2024 | 8,240 | $660.83K | Nov 14, 2024 | Options Granted - 07/29/2024 |
Congress trades
2 trades in Praxis Precision Medicines reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Sep 29, 2026 | $1K–15K | Oct 12, 2026 |
| Gilbert Cisneros CA31 | Bought | Jul 30, 2026 | $1K–15K | Sep 4, 2026 |
See a number that looks wrong?